Article
Hematology
Hemant S. Murthy, Mei-Jie Zhang, Karen Chen, Sairah Ahmed, Uday Deotare, Siddhartha Ganguly, Ankit Kansagra, Fotios V. Michelis, Taiga Nishihori, Mrinal Patnaik, Muhammad Bilal Abid, Mahmoud Aljurf, Yasuyuki Arai, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Karen Ballen, Minoo Battiwalla, Amer Beitinjaneh, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie I. Brown, Rodrigo Martino, Jean-Yves Cahn, Paul Castillo, Jan Cerny, Saurabh Chhabra, Edward Copelan, Andrew Daly, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Cesar O. Freytes, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Omer Jamy, Jacinth Joseph, Christopher G. Kanakry, Nandita Khera, Maxwell M. Krem, Yachiyo Kuwatsuka, Hillard M. Lazarus, Lazaros J. Lekakis, Hongtao Liu, Dipenkumar Modi, Pashna N. Munshi, Alberto Mussetti, Neil Palmisiano, Sagar S. Patel, David A. Rizzieri, Sachiko Seo, Mithun Vinod Shah, Akshay Sharma, Melhm Sohl, Scott R. Solomon, Matthew Ulrickson, Celalettin Ustun, Marjolein van der Poel, Leo F. Verdonck, John L. Wagner, Trent Wang, Baldeep Wirk, Amer Zeidan, Mark Litzow, Partow Kebriaei, Christopher S. Hourigan, Daniel J. Weisdorf, Wael Saber, Mohamed A. Kharfan-Dabaja
Summary: This study analyzed the outcomes of allo-HCT in BPDCN patients and found that it provides durable remissions and long-term survival. Younger age and allo-HCT in CR1 were associated with improved survival, while the use of MAC-TBI reduced relapse risk and improved DFS. Further research and innovative strategies are needed to improve the outcomes of BPDCN.
Review
Hematology
Zachariah DeFilipp, Mehrdad Hefazi, Yi-Bin Chen, Bruce R. Blazar
Summary: This article discusses the application of transplantation in the treatment of congenital or acquired nonmalignant blood diseases. Unlike patients with hematologic malignancies, the priority for nonmalignant blood disease patients is to avoid graft-versus-host disease, and emerging therapeutic methods hold promise for advancing transplantation care.
Review
Oncology
Amar H. Kelkar, Joseph H. Antin, Roman M. Shapiro
Summary: This review summarizes the most common long-term complications of hematopoietic cell transplantation (HCT) and emphasizes the importance of recognizing and managing these complications in survivorship care.
FRONTIERS IN ONCOLOGY
(2023)
Review
Medicine, General & Internal
Mattia Algeri, Pietro Merli, Franco Locatelli, Daria Pagliara
Summary: Allogeneic hematopoietic stem cell transplantation (HSCT) provides a potentially curative treatment for high-risk or relapsed acute leukemia in children by combining intense preparative radio/chemotherapy with the graft-versus-leukemia (GvL) effect. Advances in donor typing, conditioning regimens, GvHD prophylaxis, and MRD-directed interventions have continuously improved transplant outcomes, expanding the potential application of allotransplantation to most patients. Simultaneously, refinements in chemotherapy protocols and targeted therapies may redefine the indications for HSCT in the future.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Urology & Nephrology
Gertjan Lugthart, Carlijn C. E. Jordans, Anne P. J. de Pagter, Dorine Bresters, Cornelia M. Jol-van der Zijde, Joell E. Bense, Roos W. G. van Rooij-Kouwenhoven, Ram N. Sukhai, Marloes Louwerens, Eiske M. Dorresteijn, Arjan C. Lankester
Summary: This study evaluated pediatric HSCT survivors and found that within ten years post-HSCT, eGFR decreased and 17% of patients developed CKD, with severe prolonged AKI being the main risk factor. Regular monitoring of eGFR, urine, and blood pressure is crucial for identifying patients at risk of CKD and providing nephroprotective interventions.
KIDNEY INTERNATIONAL
(2021)
Article
Hematology
Sanam Shahid, Nicholas Ceglia, Jean-Benoit Le Luduec, Andrew Mcpherson, Barbara Spitzer, Theodota Kontopoulos, Viktoria Bojilova, M. Kazim Panjwani, Mikhail Roshal, Sohrab P. Shah, Omar Abdel-Wahab, Benjamin Greenbaum, Katharine C. Hsu
Summary: This study investigated the effects of allo-HCT on AML cells using a novel single-cell proteogenomic approach. The results demonstrated immune-related transcriptional signatures in posttransplant relapses, revealing dysfunction in activated natural killer cells and CD8+ T-cell subsets, as well as an expansion of dysfunctional T cells.
Article
Hematology
Brandon J. Blue, Ruta Brazauskas, Karen Chen, Jinalben Patel, Amer M. Zeidan, Amir Steinberg, Karen Ballen, Janette Kwok, Seth J. Rotz, Miguel Angel Diaz Perez, Amar H. Kelkar, Siddhartha Ganguly, John R. Wingard, Deepesh Lad, Akshay Sharma, Sherif M. Badawy, Hillard M. Lazarus, Hasan Hashem, David Szwajcer, Jennifer M. Knight, Neel S. Bhatt, Kristin Page, Sara Beattie, Yasuyuki Arai, Hongtao Liu, Staci D. Arnold, Cesar O. Freytes, Muhammad Bilal Abid, Amer Beitinjaneh, Nosha Farhadfar, Baldeep Wirk, Lena E. Winestone, Vaibhav Agrawal, Jaime M. Preussler, Sachiko Seo, Shahrukh Hashmi, Leslie Lehmann, William A. Wood, Hemalatha G. Rangarajan, Wael Saber, Navneet S. Majhail
Summary: This study compared long-term outcomes among 1-year allogeneic HCT survivors and analyzed them by race/ethnicity and socioeconomic status. The results showed no significant associations between race/ethnicity, neighborhood poverty level, and long-term outcomes among adult allogeneic HCT recipients who survived at least 1 year in remission.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Oncology
Sanghee Hong, Ruta Brazauskas, Kyle M. Hebert, Siddhartha Ganguly, Hisham Abdel-Azim, Miguel Angel Diaz, Sara Beattie, Stefan O. Ciurea, David Szwajcer, Sherif M. Badawy, Alois A. Gratwohl, Charles LeMaistre, Mahmoud D. S. M. Aljurf, Richard F. Olsson, Neel S. Bhatt, Nosha Farhadfar, Jean A. Yared, Ayami Yoshimi, Sachiko Seo, Usama Gergis, Amer M. Beitinjaneh, Akshay Sharma, Hillard Lazarus, Jason Law, Matthew Ulrickson, Hasan Hashem, Helene Schoemans, Jan Cerny, David Rizzieri, Bipin N. Savani, Rammurti T. Kamble, Bronwen E. Shaw, Nandita Khera, William A. Wood, Shahrukh Hashmi, Theresa Hahn, Stephanie J. Lee, J. Douglas Rizzo, Navneet S. Majhail, Wael Saber
Summary: This study analyzed the impact of community health status on allogeneic HCT outcomes using data from CHRR and CIBMTR, finding that patients residing in counties with a worse community health status have inferior survival due to increased risk of NRM after allogeneic HCT. There was no significant association between the community health status of the transplant center location and allogeneic HCT outcomes.
Article
Immunology
Elisa B. Margolis, Gabriela Maron Alfaro, Yilun Sun, Ronald H. Dallas, Kim J. Allison, Jose Ferrolino, Hailey S. Ross, Amy E. Davis, Qidong Jia, Paige Turner, Victoria Mackay, Cara E. Morin, Brandon M. Triplett, Eileen J. Klein, Janet A. Englund, Li Tang, Randall T. Hayden
Summary: This study explores the correlation between gut microbiota and infection risk in pediatric allogeneic hematopoietic cell transplantation (allo-HCT). It finds that disruptions in the gut microbiome are related to infection risk in pediatric allo-HCT, and different microbiota patterns are associated with different infections. The ratios of specific bacteria types in the gut can predict the risk of bacteremia, bacterial infections, and viral enterocolitis.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Hematology
Robert Chiesa, Jaap Jan Boelens, Christine N. Duncan, Jorn-Sven Kuhl, Caroline Sevin, Neena Kapoor, Vinod K. Prasad, Caroline A. Lindemans, Simon A. Jones, Hernan M. Amartino, Mattia Algeri, Nancy Bunin, Cristina Diaz-de-Heredia, Daniel J. Loes, Esther Shamir, Alison Timm, Elizabeth McNeil, Andrew C. Dietz, Paul J. Orchard
Summary: A study found that allogeneic hematopoietic stem cell transplantation can stabilize neurologic function and improve survival in patients with early cerebral adrenoleukodystrophy. The donor source, donor match, conditioning regimen, and disease stage all have an impact on the outcomes of the transplantation. However, there are associated risks such as transplant-related mortality, graft failure, and graft-versus-host disease.
Article
Immunology
Lilli Leimi, Jessica R. Koski, Outi Kilpivaara, Kim Vettenranta, A. Inkeri Lokki, Seppo Meri
Summary: This study investigated genetic complement system variants in patients with documented endotheliopathy and found that variants in complement genes may be related to endotheliopathy and poor prognosis in these patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Francesco Baldo, Roberto Simeone, Annalisa Marcuzzi, Antonio Giacomo Grasso, Rossella Vidimari, Francesca Ciriello, Davide Zanon, Alessandra Maestro, Egidio Barbi, Natalia Maximova
Summary: This study found that total amylases (TA) can serve as a valuable predictor of post-transplant overall survival and increased risk of leukemia relapse. TA values below 374 U/L were correlated with higher overall survival, while the highest TA values were associated with a high disease-progression mortality rate. Elevated TA values were also connected with significantly higher levels of proinflammatory cytokines.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Muhammad Umair Mushtaq, Moazzam Shahzad, Ezza Tariq, Qamar Iqbal, Sibgha Gull Chaudhary, Muhammad U. Zafar, Iqra Anwar, Nausheen Ahmed, Rajat Bansal, Anurag K. Singh, Sunil H. Abhyankar, Natalie S. Callander, Peiman Hematti, Joseph P. McGuirk
Summary: A systematic review and meta-analysis evaluated the outcomes of mismatched unrelated donor hematopoietic stem cell transplantation (MMUD-HSCT). The results showed that MMUD-HSCT had favorable treatment outcomes and an acceptable toxicity profile in patients lacking HLA-matched or haploidentical donors, thus expanding the accessibility of HSCT to underrepresented populations.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Jintao Xia, Xuejie Li, Genyong Gui, Jian Wu, Shengnan Gong, Yuxin Shang, Jun Fan
Summary: This study evaluated the early immune response of recipients with disparate HCMV outcomes and found that HCMV-specific IFN-gamma secreting cells, HCMV IgG, and absolute lymphocyte count could represent the humoral and cellular immune response. Early monitoring of these immune markers could enable prediction of HCMV outcomes posttransplant and assessment of the severity of HCMV DNAemia.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Medicine, General & Internal
Jiayu Wang, Meng Yuan, Guanghua Zhu, Runhui Wu, Chenguang Jia, Bin Wang, Jie Zheng, Jie Ma, Maoquan Qin, Sidan Li
Summary: This study analyzed the immune reconstitution of pediatric patients with aplastic anemia after hematopoietic stem-cell transplantation (HSCT) and found that early rapid immune reconstitution is a good predictor of clinical prognosis in children with AA.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2022)
Article
Public, Environmental & Occupational Health
Caitlin W. Elgarten, William R. Otto, Luke Shenton, Madison T. Stein, Joseph Horowitz, Catherine Aftandilian, Staci D. Arnold, Kira O. Bona, Emi Caywood, Anderson B. Collier, M. Monica Gramatges, Meret Henry, Craig Lotterman, Kelly Maloney, Arunkumar J. Modi, Amir Mian, Rajen Mody, Elaine Morgan, Elizabeth A. Raetz, Anupam Verma, Naomi Winick, Jennifer J. Wilkes, Jennifer C. Yu, Richard Aplenc, Brian T. Fisher, Kelly D. Getz
Summary: There is no significant association between CVAD type and BSI occurrence during neutropenia in pediatric AML patients.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
(2023)
Article
Oncology
Nichole Slick, Prasad Bodas, Sherif M. Badawy, Beth Wildman
Summary: This study assessed the accuracy of information about sickle cell disease (SCD) posted on social media and found that less than half of the information was accurate. This has serious implications for individuals with SCD and their caregivers who rely on social media for information.
PEDIATRIC HEMATOLOGY AND ONCOLOGY
(2023)
Article
Cell & Tissue Engineering
Senthil Velan Bhoopalan, Jonathan S. Yen, Rachel M. Levine, Akshay Sharma
Summary: Genome editing technologies, specifically CRISPR-Cas9, have made significant progress in precise genome alterations for the treatment of inherited hematopoietic disorders. Despite ongoing clinical trials and promising pre-clinical models, challenges still remain in ensuring safety, accessibility, and improving the manufacturing processes of these therapies. This review highlights recent advances and ongoing challenges in genome editing of hematopoietic stem and progenitor cells.
Article
Oncology
Michael Boyiadzis, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Minoo Battiwalla, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie Brown, Paul Castillo, Jan Cerny, Edward A. Copelan, Charles Craddock, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Christen L. Ebens, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Madiha Iqbal, Omer Jamy, Mohamed A. Kharfan-Dabaja, Nandita Khera, Hillard M. Lazarus, Richard Lin, Dipenkumar Modi, Sunita Nathan, Taiga Nishihori, Sagar S. Patel, Attaphol Pawarode, Akshay Sharma, Melhem Solh, John L. Wagner, Trent Wang, Kirsten M. Williams, Lena E. Winestone, Baldeep Wirk, Christopher S. Hourigan, Mark Litzow, Partow Kebriaei, Marcos de Lima, Kristin Page, Daniel J. Weisdorf
Summary: We investigated the impact of the number of induction/consolidation cycles on the outcomes of adult AML patients who received allo-HCT between 2008 and 2019. Our findings suggest that the number of induction cycles to complete remission (CR) has an impact on overall survival (OS) in patients who received myeloablative conditioning, with better OS observed in patients who achieved CR after 1 cycle compared to those who required 2 cycles or more. In contrast, the number of induction cycles did not affect OS in patients who received reduced-intensity conditioning. Consolidation therapy prior to allo-HCT was associated with improved OS in patients who achieved CR after 1 cycle. The presence of detectable minimal residual disease (MRD) at the time of allo-HCT did not impact outcomes in myeloablative allo-HCT, but was associated with an increased risk of relapse in reduced-intensity allo-HCT. Allo-HCT in patients with primary induction failure had significantly worse OS compared to allo-HCT in patients who achieved CR after 1-3 cycles.
Letter
Hematology
Cara E. Morin, Akshay Sharma, Subodh Selukar, Gary Beasley, Anthony Merlocco, Chris Goode, Parul Rai, Jeffrey A. Towbin, Jane S. Hankins, Jason N. Johnson
Article
Oncology
Kathryn King, Stephanie Cai, Leonardo Barrera, Paavani Reddy, Mallorie B. Heneghan, Sherif M. Badawy
Summary: This study aimed to investigate barriers to hydroxyurea adherence and evaluate their impact on adherence. The results showed that patients with good adherence had fewer barriers. Understanding barriers to adherence is crucial for improving adherence.
PEDIATRIC BLOOD & CANCER
(2023)
Article
Hematology
Richa Shah, Aashaka Shah, Sherif M. Badawy
Summary: Regular blood transfusions in thalassemia patients can lead to iron overload and related complications. Deferiprone, one of the FDA-approved iron chelators, is effective at reducing iron levels and has gained approval for twice-daily administration.
EXPERT REVIEW OF HEMATOLOGY
(2023)
Review
Hematology
Alex Pizzo, Jerlym S. Porter, Yvonne Carroll, Adam Burcheri, Matthew P. Smeltzer, Molly Beestrum, Chinonyelum Nwosu, Sherif M. Badawy, Jane S. Hankins, Lisa M. Klesges, Nicole M. Alberts
Summary: Sickle cell disease is associated with frequent painful events and organ damage. Hydroxyurea is the recommended treatment, but prescription rates are low. Provider barriers include doubts around patient adherence, concerns about side effects, lack of knowledge, cost, and patient concerns. Provider attitudes and knowledge play a role in prescription rates.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Cara E. Morin, Amy B. Kolbe, Adina Alazraki, Govind B. Chavhan, Annie Gill, Juan Infante, Geetika Khanna, HaiThuy N. Nguyen, Allison F. O'Neill, Mitchell A. Rees, Akshay Sharma, James E. Squires, Judy H. Squires, Ali B. Syed, Elizabeth R. Tang, Alexander J. Towbin, Gary R. Schooler
Summary: Treatment-induced liver injury is common in children undergoing cancer therapy and can occur during and after treatment. It can result in various acute and long-term effects, including liver failure. Quantitative imaging techniques can be useful for diagnosing and monitoring liver injury. Treatment-related liver lesions and infections can be mistaken for cancer recurrence or liver metastases, but imaging features can help differentiate them. Radiologic evaluation is essential for diagnosing and monitoring hepatic complications of cancer therapy in pediatric patients.
Article
Oncology
Ozgur Ates, Jinsoo Uh, Fakhriddin Pirlepesov, Chia-Ho Hua, Brandon Triplett, Amr Qudeimat, Akshay Sharma, Thomas E. Merchant, John T. Lucas Jr
Summary: This study addresses the challenge of respiratory motion in pediatric patients undergoing proton therapy for total lymphoid irradiation (TLI). The research concludes that 4D plan evaluation and robust optimization techniques can help address respiratory motion challenges in proton TLI treatments. Patient-specific respiratory motion evaluations are crucial to ensure adequate dosimetric coverage in proton therapy for pediatric patients.
Review
Oncology
Senthil Velan Bhoopalan, Shruthi Suryaprakash, Akshay Sharma, Marcin W. Wlodarski
Summary: Diamond-Blackfan anemia is a common genetic cause of bone marrow failure in children, characterized by anemia and bone marrow hypoplasia. It is associated with congenital anomalies, immunodeficiency, and increased risk of malignancies. Corticosteroids provide temporary relief for anemia, but most patients require lifelong blood transfusions. Allogeneic hematopoietic cell transplantation is a potential curative option, but with significant risks. Autologous genetic therapies are being developed to address the lack of suitable donors.
FRONTIERS IN ONCOLOGY
(2023)
Article
Hematology
Akshay Sharma, Brent Logan, Noel Estrada-Merly, Leslie E. Lehmann, Hemalatha G. Rangarajan, Jaime M. Preussler, Jesse D. Troy, Luke P. Akard, Neel S. Bhatt, Tony H. Truong, William A. Wood, Christopher Strouse, Mark Juckett, Nandita Khera, Douglas Rizzo, Wael Saber
Summary: This article focuses on the impact of public reporting of transplantation center performance on patient volumes. The study found that if a center has a lower than expected survival rate, the number of patients in the following year will decrease. In contrast, neighboring centers to those with lower survival rates experienced an increase in patient volumes.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Rahul Banerjee, Amar H. Kelkar, Urshila Durani, Theodora Anagnostou, Miki Nishitani, Kanwaldeep Mallhi, Navneet S. Majhail, Aaron C. Logan
Summary: Recent guidelines from the American Society for Transplantation and Cellular Therapy have aimed to establish expectations for participants in blood and marrow transplantation (BMT) and cellular therapy (CT) fellowships. A survey was conducted to examine the demographics, motivations, and experiences of recent participants in BMT/CT fellowships. The results showed that the fellowship training had a positive impact on participants' comfort with BMT/CT management and the majority would highly recommend this training to others.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Sagar S. Patel, Sanghee Hong, Lisa Rybicki, Stephanie Farlow, Jane Dabney, Matt Kalaycio, Ronald Sobecks, Navneet S. Majhail, Betty K. Hamilton
Summary: Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic cell transplantation (HCT), causing significant physical and psychosocial symptoms. This pilot study aimed to assess the feasibility of using patient-reported outcome (PRO) measures to evaluate symptom burden and quality of life (QOL) in acute GVHD. The study utilized surveys from various PRO measures and found that patients with acute GVHD had lower QOL scores compared to those without or with mild GVHD. The PRO-CTCAE captured several common symptoms of acute GVHD. Challenges in implementing PRO measures in acute GVHD were identified. Further research is needed to make PROs feasible in this patient population.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Rajshekhar Chakraborty, Jean Yi, Lisa Rybicki, Jaime Preussler, Abhinav Deol, Alison Loren, Bipin Savani, Heather S. L. Jim, Jan Cerny, Jana Reynolds, Jennifer Whitten, John R. Wingard, Joseph P. McGuirk, Joseph Uberti, Nandita Khera, Patrick Stiff, Samantha M. Jaglowski, Shahrukh Hashmi, Shernan G. Holtan, Steven Devine, Theresa Hahn, Victoria L. Whalen, Wael Saber, William Wood, K. Scott Baker, Karen Syrjala, Navneet S. Majhail
Summary: Survivors of autologous hematopoietic cell transplantation (AHCT) for multiple myeloma in stable remission do not have clinically meaningful worsening in physical functioning compared to the general population. However, they may experience distress related to health burden, uncertainty, and finances. Adherence to preventive care guidelines is high, but adherence to exercise and diet guidelines is relatively low.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)